HemoVisionAI is our flagship R&D project soon to launch as an innovative new start-up.

HemoVisionAI is a cloud-based, AI-integrated telehaematology platform built to modernise and scale blood film diagnostics. It directly addresses inefficiencies in referral pathways and enables intelligent triage—solving critical pain points in both developed and resource-constrained healthcare systems. Purpose-built for haematology laboratories and healthcare providers. HemoVisionAI streamlines workflows, reduces diagnostic delays, and lowers operational costs. In a market strained by a global shortage of haematologists and morphologists, our platform delivers faster, more accurate, and scalable interpretation—unlocking significant clinical and economic value across a multi-billion-pound global healthcare landscape.

.

Introduction

At Optymum SS, we are committed to building accessible, cost-effective, and innovative life science solutions. As part of this mission, we are developing HemoVisionAI, as a next-gen digital haematology platform..

The Problem

Haematological disorders—ranging from anaemia and leukaemia to countless morphological abnormalities—impact an estimated 2.5 billion people globally. Full Blood Count (FBC) is the most ordered lab test in the world, with 10+ million performed daily. Of these, up to 2 million per day require follow-up blood film analysis—a labour-intensive process heavily dependent on a dwindling pool of expert haematologists and morphologists.

This is not just a problem in low-resource settings. Even advanced healthcare systems face rising demand, outdated workflows, and critical workforce shortages, resulting in delays, diagnostic errors, and costly inefficiencies. Manual, paper-based referrals—often involving handwritten forms, phone calls, and unstructured emails—create significant bottlenecks, poor traceability, and inconsistent turnaround times.

These systemic inefficiencies present a massive, largely untapped opportunity to modernise an essential diagnostic workflow.

.

Our Solution: HemoVisionAI

Our 3-phase roadmap has been updated to better align with user feedback and current system needs:

Phase 1: HemoRefer – Modernising the Referral Workflow

We start by replacing outdated, manual referral processes with HemoRefer—a secure, digital referral and collaboration platform purpose-built for haematology labs.

By integrating with third-party whole-slide scanners, HemoRefer allows blood films to be digitised, annotated, and seamlessly referred, even across institutions. The result: faster decisions, fewer errors, and an auditable, scalable system fit for the demands of modern healthcare.

.Phase 2: MaaS and Telehaematology

Building on HemoRefer, this phase introduces our Morphology-as-a-Service (MaaS) model, offering healthcare providers access to a global network of expert haematologists for second opinions, case reviews, and remote consultations.
This telehaematology infrastructure will improve diagnostic access, especially in underserved settings and across time zones.

Phase 3: AI-Powered Triage

In the final phase HemoVisionAI evolves into an advanced AI-powered triage. Rather than attempting full automation, our AI model will first focus on triaging blood films. Using advanced computer vision algorithms, the system will prioritise urgent or abnormal cases, flag morphological anomalies and reduce human workload while preserving expert oversight. This triage-first strategy ensures safe AI integration into clinical workflows while unlocking real-time value and efficiency.

.Join the waiting list today!